CG Oncology Statistics

Total Valuation

CG Oncology has a market cap or net worth of $2.28 billion. The enterprise value is $1.74 billion.

Market Cap	2.28B
Enterprise Value	1.74B

Important Dates

The next estimated earnings date is Monday, February 10, 2025, before market open.

Earnings Date	Feb 10, 2025
Ex-Dividend Date	n/a

Share Statistics

CG Oncology has 76.13 million shares outstanding. The number of shares has increased by 1,143.67% in one year.

Current Share Class	76.13M
Shares Outstanding	76.13M
Shares Change (YoY)	+1,143.67%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	1.03%
Owned by Institutions (%)	66.59%
Float	62.58M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	3,366.53
PB Ratio	3.77
P/TBV Ratio	4.25
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2,543.38
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 35.32, with a Debt / Equity ratio of 0.00.

Current Ratio	35.32
Quick Ratio	34.60
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -19.76% and return on invested capital (ROIC) is -16.27%.

Return on Equity (ROE)	-19.76%
Return on Assets (ROA)	-15.69%
Return on Invested Capital (ROIC)	-16.27%
Return on Capital Employed (ROCE)	-17.88%
Revenue Per Employee	$11,213
Profits Per Employee	-$1.29M
Employee Count	61
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -16.36% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-16.36%
50-Day Moving Average	30.80
200-Day Moving Average	33.85
Relative Strength Index (RSI)	48.52
Average Volume (20 Days)	630,991

Short Selling Information

The latest short interest is 6.37 million, so 8.37% of the outstanding shares have been sold short.

Short Interest	6.37M
Short Previous Month	6.90M
Short % of Shares Out	8.37%
Short % of Float	10.19%
Short Ratio (days to cover)	7.17

Income Statement

In the last 12 months, CG Oncology had revenue of $684,000 and -$78.73 million in losses. Loss per share was -$1.69.

Revenue	684,000
Gross Profit	-70.96M
Operating Income	-95.97M
Pretax Income	n/a
Net Income	-78.73M
EBITDA	-95.94M
EBIT	-95.97M
Loss Per Share	-$1.69

Full Income Statement

Balance Sheet

The company has $540.71 million in cash and $296,000 in debt, giving a net cash position of $540.41 million or $7.10 per share.

Cash & Cash Equivalents	540.71M
Total Debt	296,000
Net Cash	540.41M
Net Cash Per Share	$7.10
Equity (Book Value)	536.77M
Book Value Per Share	7.95
Working Capital	536.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$72.70 million and capital expenditures -$25,000, giving a free cash flow of -$72.72 million.

Operating Cash Flow	-72.70M
Capital Expenditures	-25,000
Free Cash Flow	-72.72M
FCF Per Share	-$0.96

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-14,030.99%
Pretax Margin	-10,642.69%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

CG Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,143.67%
Shareholder Yield	-1,143.67%
Earnings Yield	-3.45%
FCF Yield	-3.19%

Analyst Forecast

The average price target for CG Oncology is $65.11, which is 117.40% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$65.11
Price Target Difference	117.40%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	288.22%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CG Oncology has an Altman Z-Score of 92.88 and a Piotroski F-Score of 3.

Altman Z-Score	92.88
Piotroski F-Score	3